文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

经鼻高流量氧疗避免SARS-CoV-2肺炎患者有创机械通气:一项回顾性研究

High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study.
PubMed 文献 · Ann Intensive Care · 2021-02-27
一句话结论重症COVID-19相关急性呼吸衰竭患者早期使用经鼻高流量氧疗与较低的有创机械通气率相关(加权倾向评分后OR 0.31,95%CI 0.14-0.66,p=0.002)。

这项双中心回顾性研究纳入2020年3月11日至5月3日巴黎地区两家三级医院ICU连续收治的COVID-19合并急性呼吸衰竭、入ICU时未接受有创机械通气的患者138例,其中单纯标准氧疗组62例(45%)、经鼻高流量氧疗组76例(55%)。主要终点为入ICU后有创机械通气率,经鼻高流量氧疗组39/76(51%)vs 标准氧疗组46/62(74%),OR 0.37(95%CI 0.18-0.76,p=0.007);加权倾向评分后经鼻高流量氧疗仍与较低的有创机械通气率相关(OR 0.31,95%CI 0.14-0.66,p=0.002)。加权倾向评分后两组ICU住院时长及第28天、第60天死亡率无显著差异,经鼻高流量氧疗组第28天无呼吸机天数更多(21天 vs 10天,p=0.005)。经鼻高流量氧疗组中与有创机械通气相关的预测因素为SAPS2评分(OR 1.13,95%CI 1.06-1.20,p=0.0002)和ROX指数>4.88(OR 0.23,95%CI 0.008-0.64,p=0.006)。

要点

  • 双中心回顾性研究纳入138例COVID-19合并急性呼吸衰竭、入ICU时未插管患者,经鼻高流量氧疗组76例、标准氧疗组62例。
  • 经鼻高流量氧疗组有创机械通气39/76(51%),标准氧疗组46/62(74%),OR 0.37(95%CI 0.18-0.76,p=0.007)。
  • 加权倾向评分后经鼻高流量氧疗仍与较低有创机械通气率相关(OR 0.31,95%CI 0.14-0.66,p=0.002)。
  • 加权倾向评分后两组第28天和第60天死亡率及ICU住院时长无显著差异,经鼻高流量氧疗组第28天无呼吸机天数更多(21天 vs 10天,p=0.005)。
  • 经鼻高流量氧疗组中有创机械通气的预测因素为SAPS2评分(OR 1.13,95%CI 1.06-1.20,p=0.0002)和ROX指数>4.88(OR 0.23,95%CI 0.008-0.64,p=0.006)。

适用人群与场景

  • 2020年3月11日至5月3日巴黎地区两家三级医院ICU连续收治的COVID-19合并急性呼吸衰竭、入ICU时未接受有创机械通气的患者。

研究设计与关键结果

  • 双中心回顾性研究,纳入138例患者,经鼻高流量氧疗组76例(55%)、标准氧疗组62例(45%),采用加权倾向评分比较。
  • 主要终点有创机械通气率:经鼻高流量氧疗组39/76(51%)vs 标准氧疗组46/62(74%),OR 0.37(95%CI 0.18-0.76,p=0.007);加权倾向评分后OR 0.31(95%CI 0.14-0.66,p=0.002)。
  • 加权倾向评分后第28天和第60天死亡率及ICU住院时长在两组间无显著差异。
  • 第28天无呼吸机天数:经鼻高流量氧疗组21天 vs 标准氧疗组10天,p=0.005。
  • 经鼻高流量氧疗组中有创机械通气的预测因素:SAPS2评分OR 1.13(95%CI 1.06-1.20,p=0.0002);ROX指数>4.88 OR 0.23(95%CI 0.008-0.64,p=0.006)。

证据类型、等级与局限

  • 证据类型:双中心回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,经鼻高流量氧疗用于COVID-19所致急性呼吸衰竭与较低的有创机械通气率相关。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The efficacy of high flow nasal canula oxygen therapy (HFNO) to prevent invasive mechanical ventilation (IMV) is not well established in severe coronavirus disease 2019 (COVID-19). The aim of this study was to compare the risk of IMV between two strategies of oxygenation (conventional oxygenation and HFNO) in critically ill COVID 19 patients.

METHODS: This was a bicenter retrospective study which took place in two intensive care units (ICU) of tertiary hospitals in the Paris region from March 11, to May 3, 2020. We enrolled consecutive patients hospitalized for COVID-19 and acute respiratory failure (ARF) who did not receive IMV at ICU admission. The primary outcome was the rate of IMV after ICU admission. Secondary outcomes were death at day 28 and day 60, length of ICU stay and ventilator-free days at day 28. Data from the HFNO group were compared with those from the standard oxygen therapy (SOT) group using weighted propensity score.

RESULTS: Among 138 patients who met the inclusion criteria, 62 (45%) were treated with SOT alone, and 76 (55%) with HFNO. In HFNO group, 39/76 (51%) patients received IMV and 46/62 (74%) in SOT group (OR 0.37 [95% CI, 0.18-0.76] p = 0.007). After weighted propensity score, HFNO was still associated with a lower rate of IMV (OR 0.31 [95% CI, 0.14-0.66] p = 0.002). Length of ICU stay and mortality at day 28 and day 60 did not significantly differ between HFNO and SOT groups after weighted propensity score. Ventilator-free days at days 28 was higher in HNFO group (21 days vs 10 days, p = 0.005). In the HFNO group, predictive factors associated with IMV were SAPS2 score (OR 1.13 [95%CI, 1.06-1.20] p = 0.0002) and ROX index > 4.88 (OR 0.23 [95%CI, 0.008-0.64] p = 0.006).

CONCLUSIONS: High flow nasal canula oxygen for ARF due to COVID-19 is associated with a lower rate of invasive mechanical ventilation.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Bonnet N, Martin O, Boubaya M, et al. High flow nasal oxygen therapy to avoid invasive mechanical ventilation in SARS-CoV-2 pneumonia: a retrospective study. Ann Intensive Care. 2021. PMID: 33638752. doi:10.1186/s13613-021-00825-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。